Impact of fgd1 and ddn Diversity in Mycobacterium tuberculosis Complex on In Vitro Susceptibility to PA-824

PA-824 is a promising drug candidate for the treatment of tuberculosis (TB). It is in phase II clinical trials as part of the first newly designed regimen containing multiple novel antituberculosis drugs (PA-824 in combination with moxifloxacin and pyrazinamide). However, given that the genes involv...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Feuerriegel, Silke, Köser, Claudio U., Baù, Davide, Rüsch-Gerdes, Sabine, Summers, David K., Archer, John A. C., Marti-Renom, Marc A., Niemann, Stefan
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Microbiology 2011
Θέματα:
Mechanisms of Resistance
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3232757/
https://ncbi.nlm.nih.gov/pubmed/21930879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.05500-11
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια